TABLE 4.
Changes of lipid profile at week 16 compared with baseline in the telmisartan/rosuvastatin SPC and telmisartan monotherapy groups
| Variables | Visit | Telmisartan (N = 38) | Telmisartan/rosuvastatin (N = 39) | Total (N = 77) | |
|---|---|---|---|---|---|
| Total cholesterol (mg/dl) | Baseline | Mean (SD) | 203.44(35.71) | 205.81(40.40) | 204.64(37.93) |
| Week 16 | Mean (SD) | 210.68(40.96) | 147.23(31.99) | 178.52(48.45) | |
| Change a | Mean (SD) | 7.09(32.30) | −59.96(36.34) | −26.90(48.03) | |
| p‐value | .196b | <.001b | <.001d | ||
| Triglyceride (mg/dl) | Baseline | Mean (SD) | 219.87(158.51) | 179.18(77.77) | 199.26(125.20) |
| Week 16 | Mean (SD) | 193.60(102.82) | 155.28(106.41) | 174.17(105.68) | |
| Change a | Mean (SD) | 6.57(96.78) | −27.33(73.05) | −10.62(86.66) | |
| p‐value | .949c | .001c | .047e | ||
| HDL‐cholesterol (mg/dl) | Baseline | Mean (SD) | 44.29(9.78) | 49.38(11.94) | 46.87(11.15) |
| Week 16 | Mean (SD) | 46.22(11.23) | 53.83(12.81) | 50.03(12.56) | |
| Change a | Mean (SD) | 1.36(6.13) | 4.25(6.55) | 2.81(6.46) | |
| p‐value | .192b | <.001b | .057d | ||
| LDL‐cholesterol (mg/dl) | Baseline | Mean (SD) | 117.09(44.74) | 123.93(35.57) | 120.56(40.24) |
| Week 16 | Mean (SD) | 129.10(32.74) | 65.32(28.05) | 96.30(44.07) | |
| Change a | Mean (SD) | 3.82(33.13) | −59.84(34.75) | −28.92(46.53) | |
| p‐value | .506b | <.001b | <.001d |
Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; LS, least square; SD, standard deviation.
a
Change = (Value at week 16) − (value at baseline) .
Difference between baseline and post‐baseline in each group (bpaired t‐test, cWilcoxon signed rank test).
Difference between control and treatment group (dpaired t‐test, etwo sample t‐test).